A Case Report Overwhelming response to TNF-alfa inhibitor Infliximab “innovator” Vs. Adalimumab “Bio-similar” in a previously therapy naive adult. Indian J Case Reports. 2022;8(3):58-61. doi:10.32677/ijcr.v8i3.3317